Address: Insure Insights 61 Bridge Street, Kington.HR5 3DJ United Kingdom

Global Microscopic Polyangiitis Treatment Market Outlook 2020: Global Opportunity and Demand Analysis, Market Forecast, 2019-2028

  • Home
  • Reports
  • Global Microscopic Polyangiitis Treatment Market Outlook 2020: Global Opportunity and Demand Analysis, Market Forecast, 2019-2028
Global Microscopic Polyangiitis Treatment Market Outlook 2020: Global Opportunity and Demand Analysis, Market Forecast, 2019-2028

Global Microscopic Polyangiitis Treatment Market Outlook 2020: Global Opportunity and Demand Analysis, Market Forecast, 2019-2028

  • Published Date: 02 Dec 2020
  • Report ID: HLT 0042
  • Pages:196
  • Base Year2019
  • Format: PDF
  • Historical Data: 2016-2019

The global Microscopic Polyangiitis (MPA) Treatment market size is projected to reach, at a CAGR of 7.5% during 2019-2028.

With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Microscopic Polyangiitis (MPA) Treatment market to help players in achieving a strong market position.

Top Driver: rising development of new treatments for MPA and robust pipeline drug

The global microscopic polyangiitis (MPA) treatment market growth is majorly driven by the rising development of new treatments for MPA and robust pipeline drugs. Some of the pipeline drugs for the treatment of microscopic polyangiitis are Abatacept, IFX 1, among othersFood and Drug Administration (FDA) approval for conducting phase II clinical trials of IFX-1 for treatment of anti-neutrophil cytoplasmic autoantibody (ANCA) vasculitis, presence of ANCA indicates that patient is suffering from microscopic polyangiitis (MPA). IFX-1, an inhibitor of the complement system, neutralizes C5a component without affecting the normal immune functions. Hence, increasing clinical trials for the development of new treatment for MPA is expected to boost the growth of microscopic polyangiitis market over the forecast period.

The increasing approvals by regulatory bodies such as the U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA), Medicines and Healthcare products Regulatory Agency (MHRA), among others for several drugs for the treatment of MPA is further driving the growth of the market.

Rituximab to Make Crucial Contribution for Growth of Global Microscopic Polyangiitis Treatment Market

The treatment of microscopic polyangiitis is predicated on several factors, including disease severity and organ involvement. Commonly, MPA is treated with corticosteroids like prednisone utilized in combination with other medications that suppress the system and reduce inflammation. However, even with treatment, MPA may be a chronic condition with periods of relapse and remission, so ongoing medical aid and monitoring is necessary. A number of the drug available for the treatment of MPA is Rituximab (Rituxan), Cyclophosphamide (Cytoxan), Azathioprine, Prednisone, Avacopan, et al. In 2011, the U.S. Food and Drug Administration (FDA) approved rituximab for the treatment of MPA and GPA. (Biologic medications are complex proteins derived from living organisms. they aim certain parts of the system to regulate inflammation.). Rituximab is predicted to realize maximum share over the forecast period 2019-2028.

 On the opposite hand, cyclophosphamide is growing at a big rate of growth over the forecast period. It’s a chemotherapy-type drug which blocks the abnormal growth of certain cells within the body, together with prednisone. Prednisone is usually started at a high dose then tapered off slowly. Cyclophosphamide lowers the body’s ability to fight infection, hence usually limited to a three- to six-month period and replaced by less toxic medications like mycophenolate mofetil and azathioprine, or methotrexate, a drug commonly won’t to treat atrophic arthritis. Some milder sorts of MPA are typically treated with a mixture of prednisone and methotrexate.

North America dominated to witness fastest growth in Global Microscopic Polyangiitis Treatment Market

North America region is dominating the worldwide microscopic polyangiitis (MPA) treatment market accounting for the utmost market share in 2019, thanks to the increasing development of medicine for the treatment of MPA. Within the us, the annual incidence of microscopic polyangiitis is 3.6 cases per million persons, and therefore the prevalence is one to 3 cases per 100,000 populations. In September 2019, Roche received the U.S. Food and Drug Administration (FDA) approval for Rituxan® (rituximab), together with glucocorticoids, for the treatment of granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) in paediatric patients two years aged and older.

On the opposite hand, Europe microscopic polyangiitis market is projected to grow at a big CAGR over the forecast period, thanks to increasing clinical trials and approval of medicine. As an example Bristol-Myers Squibb Company is conducting phase III clinical trial clinical trials for Abatacept (Orencia), which is predicted to be completed by September 2022. Orencia may be a recombinant protein that inhibits the T cell activation pathway thereby suppressing the system.

Players to Focus on Microscopic Polyangiitis Treatment Market

The microscopic polyangiitis (MPA) treatment market is very competitive and consists of several major players and emergence of latest players within the market. A number of the key players which are contributing to the expansion of the market are

  • ChemoCentryx Inc.,
  • Celltrion, Inc.,
  • Teijin Pharma Ltd,
  • Sandoz International GmbH (Novartis Division),
  • TTY Biopharm Company Ltd,
  • Genentech, Inc.,
  • InflaRx N.V.,
  • Bristol-Myers Squibb Company,
  • Amerigen Pharmaceuticals Limited,

The main players are adopting several growth strategies like product launches, clinical trials, acquisitions, and collaborations, which are contributing to the expansion of the microscopic polyangiitis (MPA) treatment market globally.

Israeli generics giant Teva Pharmaceutical Industries; on 4th May 2020, Israeli generics giant Teva Pharmaceutical Industries and partner, South Korean biotechnology company Celltrion, launched their rituximab biosimilar Truxima (TL011) within the US. Truxima (rituximab-abbs) is now available within the US for treatment of patients with non-Hodgkin’s lymphoma (NHL), chronic lymphocytic leukaemia (CLL), atrophic arthritis , granulomatosis with polyangiitis (Wegener’s granulomatosis) and microscopic polyangiitis.

Pfizer In January 2020, Pfizer announced to introduce three new biosimilars this year. the corporate plans to launch Avastin biosimilar Zirabev (bevacizumab-bvzr); Rituxan biosimilar Ruxience (rituximab-pvvr); and Herceptin biosimilar Trazimera (trastuzumab-qyyp). Ruxience is out there for the treatment of adult patients with non-Hodgkin’s lymphoma, chronic leukemia , and granulomatosis with polyangiitis and microscopic polyangiitis.

Scope of the Report

By Type

  • Avacopan
  • Immune Globulin
  • Rituximab Biosimila

By Application

  • Hospital
  • Clinic

By Region

  • North America
  • Europe
  • Asia Pacific
  • SAMEA

Key Reasons to Purchase this Report 

  1. It provides a technological development map over time to understand the growth rate of the industry.
  1. The report offers a dynamic method to various factors that drive or restrain the growth of the market.
  1. It renders definite analysis for changing competitive dynamics.
  1. It builds a seven-year estimate based on how the market is predicted to grow.

Chapter 1          Overview And Scope

1.1            Market Vision

1.1.1        Market Definition

1.1.2        Market Scope

1.2            Market Segmentation

Chapter 2          Our Research Practice

2.1            Our Research Methodology

2.2            Data Triangulation

2.3            Data Sources

2.4            Assumptions for the study

2.5            Approach Adopted

Chapter 3          Executive Summary

3.1            Market Snapshot

3.2            Regional Snapshot

3.3            Segment Summary

Chapter 4          Covid-19 Impact Analysis

4.1            Overview

4.2            Prevalence analysis

4.3            Key Factor Impact Analysis

Chapter 5          Global Sleep Apnea Devices Market Forces

5.1            What’s Driving the Market

5.2            Porter’s Five Forces Analysis

5.2.1        Power of Suppliers

5.2.2        Threats From New Entrants

5.2.3        Power of Buyer

5.2.4        Threat From Substitute Product

5.2.5        Degree of Competition

Chapter 6          Global Sleep Apnea Devices Market -Industry Snapshots

6.1            Overview

6.1.1        Global Sleep Apnea Devices Market Value, 2019 – 2028, (US$ Bn)

6.2            Market Overview

6.2.1        Drivers Analysis

6.2.2        Restraint/Challenges analysis

6.2.3        Opportunity Analysis

6.3            Supply Chain/Value Chain Analysis

6.4            Market SWOT Analysis

Chapter 7          Global Sleep Apnea Devices Market Analysis, by Diagnostic Devices

7.1            Overview

7.2            Key Findings for Sleep Apnea Devices Market- By Diagnostic Devices

7.2.1        Sleep Apnea Devices Market- Pulse oximeters

7.2.2        Sleep Apnea Devices Market- Actigraphy devices

7.2.3        Sleep Apnea Devices Market- Polysomnography Devices

Chapter 8          Global Sleep Apnea Devices Market Analysis, by Therapeutic Devices

8.1            Overview

8.2            Key Findings for Sleep Apnea Devices Market- By Therapeutic Devices

8.2.1        Sleep Apnea Devices Market- Oxygen Devices

8.2.2        Sleep Apnea Devices Market- Positive Airways Pressure Devices

8.2.3        Sleep Apnea Devices Market- Oral Appliances

8.2.4        Sleep Apnea Devices Market- Others

Chapter 9          Sleep Apnea Devices Market Analysis by Region

9.1            Key Findings for Sleep Apnea Devices Market- By region

9.2            Overview

9.2.1        Global Sleep Apnea Devices Market Analysis, By Diagnostic Devices, 2019 – 2028

9.2.2        Global Sleep Apnea Devices Market Analysis, By Therapeutic Devices, 2019 – 2028

9.3            Sleep Apnea Devices Market – North America

9.3.1        Overview

9.3.2        U.S.

9.3.3        Canada

9.3.4        Mexico

9.3.5        North America Market, By Diagnostic Devices

9.3.6        North America Market, By Therapeutic Devices

9.4            Sleep Apnea Devices Market – Europe

9.4.1        Overview

9.4.2        Germany

9.4.3        United Kingdom

9.4.4        France

9.4.5        Italy

9.4.6        Rest Of Europe

9.4.7        Europe Market, By Diagnostic Devices

9.4.8        Europe Market, By Therapeutic Devices

9.5            Sleep Apnea Devices Market – Asia Pacific

9.5.1        Overview

9.5.2        China

9.5.3        Japan

9.5.4        India

9.5.5        Rest of APAC

9.5.6        Asia Pacific Market, By Diagnostic Devices

9.5.7        Asia Pacific Market, By Therapeutic Devices

9.6            Sleep Apnea Devices Market – SAMEA

9.6.1        Overview

9.6.2        Middle East & Africa (MEA)

9.6.3        South America

9.6.4        Rest Of World

9.6.5        South America, Middle East and Africa Market, By Diagnostic Devices

9.6.6        South America, Middle East and Africa Market, By Therapeutic Devices

Chapter 10      Market Competition Analysis

10.1          Market Share/Positioning Analysis

10.1.1      Market Positioning of Key Vendors, 2019

10.1.2      Key Strategies Adopted by the Leading Players

10.1.3      Recent Developments

Chapter 11      Company Profiles- Snapshot

11.1          Curative Medical Inc

11.1.1      Business Fundamentals

11.1.2      Financial Snapshots

11.1.3      Product Portfolio

11.1.4      Recent Developments

11.2          Philips Respironics

11.3          ResMed

11.4          Fisher & Paykel Healthcare

11.5          Cadwell Laboratories

11.6          Invacare Corporation

*More than 10 Companies are profiled in this Research Report*

*Financials would be provided on a best efforts basis for private companies”

Chapter 12      Appendix

List of Figures

 

FIG. 1          Global Sleep Apnea Devices: Market Segmentation

FIG. 2          Global Sleep Apnea Devices Market: Research Methodology

FIG. 3          Top-Down and Bottom Up Approach

FIG. 4          Market Snapshot

FIG. 5          Porter’s Five Forces Analysis

FIG. 6          Global Sleep Apnea Devices Market Value, 2019 – 2028, (US$ Bn)

FIG. 7          Supply Chain/Value Chain Analysis

FIG. 8          Global Sleep Apnea Devices Market Value Contribution, By Diagnostic Devices, 2019 & 2026 (%)

FIG. 9          Global Sleep Apnea Devices Market Value Contribution, By Therapeutic Devices, 2019 & 2026 (%)

FIG. 10        Global Sleep Apnea Devices Market Value, 2019 – 2028, (US$ Bn)

FIG. 11        North America Sleep Apnea Devices Market Value, 2019 – 2028, (US$ Bn)

FIG. 12        Sleep Apnea Devices Market Segment 1 – North America

FIG. 13        Sleep Apnea Devices Market Segment 2 – North America

FIG. 14        Sleep Apnea Devices U.S. outlook, 2019 & 2026

FIG. 15        Sleep Apnea Devices Canada outlook, 2019 & 2026

FIG. 16        Sleep Apnea Devices Mexico outlook, 2019 & 2026

FIG. 17        Europe Sleep Apnea Devices Market Value, 2019 – 2028, (US$ Bn)

FIG. 18        Sleep Apnea Devices Market Segment 1 – Europe

FIG. 19        Sleep Apnea Devices Market Segment 2 – Europe

FIG. 20        Sleep Apnea Devices Germany outlook, 2019 & 2026

FIG. 21        Sleep Apnea Devices United Kingdom outlook, 2019 & 2026

FIG. 22        Sleep Apnea Devices France outlook, 2019 & 2026

FIG. 23        Sleep Apnea Devices Italy outlook, 2019 & 2026

FIG. 24        Sleep Apnea Devices Rest Of Europe outlook, 2019 & 2026

FIG. 25        Asia Pacific Sleep Apnea Devices Market Value, 2019 – 2028, (US$ Bn)

FIG. 26        Sleep Apnea Devices Market Segment 1 – Asia Pacific

FIG. 27        Sleep Apnea Devices Market Segment 2 – Asia Pacific

FIG. 28        Sleep Apnea Devices China outlook, 2019 & 2026

FIG. 29        Sleep Apnea Devices Japan outlook, 2019 & 2026

FIG. 30        Sleep Apnea Devices India outlook, 2019 & 2026

FIG. 31        Sleep Apnea Devices Rest of APAC outlook, 2019 & 2026

FIG. 32        SAMEA Sleep Apnea Devices Market Value, 2019 – 2028, (US$ Bn)

FIG. 33        Sleep Apnea Devices Market Segment 1 – SAMEA

FIG. 34        Sleep Apnea Devices Market Segment 2 – SAMEA

FIG. 35        Sleep Apnea Devices Middle East & Africa (MEA) outlook, 2019 & 2026

FIG. 36        Sleep Apnea Devices South America outlook, 2019 & 2026

FIG. 37        Sleep Apnea Devices Rest Of World outlook, 2019 & 2026

 

List of Tables

 

TABLE 1      Sleep Apnea Devices market by Diagnostic Devices 1, 2019 – 2028 (USD Million)

TABLE 2      Sleep Apnea Devices market by Diagnostic Devices 2, 2019 – 2028 (USD Million)

TABLE 3      Sleep Apnea Devices market by Diagnostic Devices 3, 2019 – 2028 (USD Million)

TABLE 4      Sleep Apnea Devices market by Therapeutic Devices 1, 2019 – 2028 (USD Million)

TABLE 5      Sleep Apnea Devices market by Therapeutic Devices 2, 2019 – 2028 (USD Million)

TABLE 6      Sleep Apnea Devices market by Therapeutic Devices 3, 2019 – 2028 (USD Million)

TABLE 7      Sleep Apnea Devices market by Therapeutic Devices 4, 2019 – 2028 (USD Million)

TABLE 8      Global Sleep Apnea Devices Market Value, By Diagnostic Devices, 2019 – 2028 (US$ Bn)

TABLE 9      Global Sleep Apnea Devices Market Value, By Therapeutic Devices, 2019 – 2028 (US$ Bn)

TABLE 10   Sleep Apnea Devices Market Analysis by North America (USD Million), 2019 – 2028

TABLE 11   U.S. Sleep Apnea Devices Market, 2019 – 2028 (USD Million)

TABLE 12   U.S. Sleep Apnea Devices Market, By Diagnostic Devices, 2019 – 2028 (USD Million)

TABLE 13   U.S. Sleep Apnea Devices Market, By Therapeutic Devices, 2019 – 2028 (USD Million)

TABLE 14   Canada Sleep Apnea Devices Market, 2019 – 2028 (USD Million)

TABLE 15   Canada Sleep Apnea Devices Market, By Diagnostic Devices, 2019 – 2028 (USD Million)

TABLE 16   Canada Sleep Apnea Devices Market, By Therapeutic Devices, 2019 – 2028 (USD Million)

TABLE 17   Mexico Sleep Apnea Devices Market, 2019 – 2028 (USD Million)

TABLE 18   Mexico Sleep Apnea Devices Market, By Diagnostic Devices, 2019 – 2028 (USD Million)

TABLE 19   Mexico Sleep Apnea Devices Market, By Therapeutic Devices, 2019 – 2028 (USD Million)

TABLE 20   Sleep Apnea Devices Market Analysis by Europe (USD Million), 2019 – 2028

TABLE 21   Germany Sleep Apnea Devices Market, 2019 – 2028 (USD Million)

TABLE 22   Germany Sleep Apnea Devices Market, By Diagnostic Devices, 2019 – 2028 (USD Million)

TABLE 23   Germany Sleep Apnea Devices Market, By Therapeutic Devices, 2019 – 2028 (USD Million)

TABLE 24   United Kingdom Sleep Apnea Devices Market, 2019 – 2028 (USD Million)

TABLE 25   United Kingdom Sleep Apnea Devices Market, By Diagnostic Devices, 2019 – 2028 (USD Million)

TABLE 26   United Kingdom Sleep Apnea Devices Market, By Therapeutic Devices, 2019 – 2028 (USD Million)

TABLE 27   France Sleep Apnea Devices Market, 2019 – 2028 (USD Million)

TABLE 28   France Sleep Apnea Devices Market, By Diagnostic Devices, 2019 – 2028 (USD Million)

TABLE 29   France Sleep Apnea Devices Market, By Therapeutic Devices, 2019 – 2028 (USD Million)

TABLE 30   Italy Sleep Apnea Devices Market, 2019 – 2028 (USD Million)

TABLE 31   Italy Sleep Apnea Devices Market, By Diagnostic Devices, 2019 – 2028 (USD Million)

TABLE 32   Italy Sleep Apnea Devices Market, By Therapeutic Devices, 2019 – 2028 (USD Million)

TABLE 33   Rest Of Europe Sleep Apnea Devices Market, 2019 – 2028 (USD Million)

TABLE 34   Rest Of Europe Sleep Apnea Devices Market, By Diagnostic Devices, 2019 – 2028 (USD Million)

TABLE 35   Rest Of Europe Sleep Apnea Devices Market, By Therapeutic Devices, 2019 – 2028 (USD Million)

TABLE 36   Sleep Apnea Devices Market Analysis by Asia Pacific (USD Million), 2019 – 2028

TABLE 37   China Sleep Apnea Devices Market, 2019 – 2028 (USD Million)

TABLE 38   China Sleep Apnea Devices Market, By Diagnostic Devices, 2019 – 2028 (USD Million)

TABLE 39   China Sleep Apnea Devices Market, By Therapeutic Devices, 2019 – 2028 (USD Million)

TABLE 40   Japan Sleep Apnea Devices Market, 2019 – 2028 (USD Million)

TABLE 41   Japan Sleep Apnea Devices Market, By Diagnostic Devices, 2019 – 2028 (USD Million)

TABLE 42   Japan Sleep Apnea Devices Market, By Therapeutic Devices, 2019 – 2028 (USD Million)

TABLE 43   India Sleep Apnea Devices Market, 2019 – 2028 (USD Million)

TABLE 44   India Sleep Apnea Devices Market, By Diagnostic Devices, 2019 – 2028 (USD Million)

TABLE 45   India Sleep Apnea Devices Market, By Therapeutic Devices, 2019 – 2028 (USD Million)

TABLE 46   Rest of APAC Sleep Apnea Devices Market, 2019 – 2028 (USD Million)

TABLE 47   Rest of APAC Sleep Apnea Devices Market, By Diagnostic Devices, 2019 – 2028 (USD Million)

TABLE 48   Rest of APAC Sleep Apnea Devices Market, By Therapeutic Devices, 2019 – 2028 (USD Million)

TABLE 49   Sleep Apnea Devices Market Analysis by SAMEA (USD Million), 2019 – 2028

TABLE 50   Middle East & Africa (MEA) Sleep Apnea Devices Market, 2019 – 2028 (USD Million)

TABLE 51   Middle East & Africa (MEA) Sleep Apnea Devices Market, By Diagnostic Devices, 2019 – 2028 (USD Million)

TABLE 52   Middle East & Africa (MEA) Sleep Apnea Devices Market, By Therapeutic Devices, 2019 – 2028 (USD Million)

TABLE 53   South America Sleep Apnea Devices Market, 2019 – 2028 (USD Million)

TABLE 54   South America Sleep Apnea Devices Market, By Diagnostic Devices, 2019 – 2028 (USD Million)

TABLE 55   South America Sleep Apnea Devices Market, By Therapeutic Devices, 2019 – 2028 (USD Million)

TABLE 56   Rest Of World Sleep Apnea Devices Market, 2019 – 2028 (USD Million)

TABLE 57   Rest Of World Sleep Apnea Devices Market, By Diagnostic Devices, 2019 – 2028 (USD Million)

TABLE 58   Rest Of World Sleep Apnea Devices Market, By Therapeutic Devices, 2019 – 2028 (USD Million)

Request for Sample

Please fill out the form to receive sample pages of the report